Sanofi and Selecta Biosciences have entered into a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies. The collaboration will leverage Selecta’s Synthetic Vaccine Particle (SVP) platform to engineer nanoparticles with the ideal structure and composition to produce immune tolerance by balancing the overactive response to specific allergy-causing antigens.
Sanofi has an exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional immunotherapies. Selecta is eligible to receive preclinical, clinical, regulatory and sales milestones totaling $300 million per allergen indication. Selecta is also entitled to royalties on sales for each commercialized immunotherapy.
“We are very pleased that Sanofi, a global leader in vaccines and immunology is entering into a partnership with Selecta to develop and commercialize products from our immunotherapy platform,” said Werner Cautreels, Ph.D., Selecta’s president and chief executive officer. “Selecta’s SVP technology can restore balance to dysregulated immune systems by producing immune tolerance to specific antigens. Our approach addresses the underlying causes of these diseases and thereby makes advances beyond today’s symptomatic treatments and allergen avoidance strategies.”